Better quality of life in aHUS with Ultomiris vs. Soliris, review finds
Both Soliris (eculizumab) and Ultomiris (ravulizumab) are safe, and have similar effectiveness in improving kidney function and blood parameters in people with atypical hemolytic syndrome (aHUS), according to a new systematic review study. However, Ultomoris “was preferred by a majority of the patients as it only has…